AOD 9604 is a synthetic hGH-derived peptide fragment with limited early-phase human trial data and no MHRA or EMA Marketing Authorisation
Side effects like nausea, vomiting, and gastrointestinal discomfort are common
On the first day of the meeting, July 23, the panel voted to approve the ever-popular "wolverine" shot, BPC-157, marketed for speedy recovery and wound healing
Clinical trials showed significant weight loss at every dose level, with 5mg producing an average of 16% body weight reduction in the SURMOUNT-1 trial
Most of the time, this soreness is mild and will go away without treatment in a few days
No lethal dose has been identified